» Articles » PMID: 32565797

Differential MicroRNA-Signatures in Thyroid Cancer Subtypes

Overview
Journal J Oncol
Specialty Oncology
Date 2020 Jun 23
PMID 32565797
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is one of the most common endocrine cancers, with an increasing trend in the last few decades. Although papillary thyroid cancer is the most frequent subtype compared with follicular or anaplastic thyroid cancer, it can dedifferentiate to a more aggressive phenotype, and the recurrence rate is high. The cells of follicular adenomas and follicular carcinomas appear identical in cytology, making the preoperative diagnosis difficult. On the other hand, anaplastic thyroid cancer poses a significant clinical challenge due to its aggressive nature with no effective therapeutic options. In the past several years, the roles of genetic alterations of thyroid tumors have been documented, with a remarkable correlation between genotype and phenotype, indicating that distinct molecular changes are associated with a multistep tumorigenic process. Besides mRNA expression profiles, small noncoding microRNA (miRNA) expression also showed critical functions for cell differentiation, proliferation, angiogenesis, and resistance to apoptosis and finally activating invasion and metastasis in cancer. Several high-throughput sequencing studies demonstrate that miRNA expression signatures contribute clinically relevant information including types of thyroid cancer, tumor grade, and prognosis. This review summarizes recent findings on miRNA signatures in thyroid cancer subtypes.

Citing Articles

ETS1 Protein Expression May Be Altered by the Complementarity of ETS1 mRNA Sequences with miR-203a-3p and miR-204-3p in Papillary Thyroid Carcinoma.

Novkovic S, Selemetjev S, Miljus J, Zivaljevic V, Dunderovic D, Milinkovic M Int J Mol Sci. 2025; 26(3).

PMID: 39941022 PMC: 11818258. DOI: 10.3390/ijms26031253.


New Horizons of Biomarkers in Metastatic Thyroid Cancer.

Cendra A, Pekarek L, Pedrejon B, Bernier L, Cervantes E, Cendra C J Cancer. 2025; 16(1):241-264.

PMID: 39744583 PMC: 11660124. DOI: 10.7150/jca.101395.


The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer.

Sabi E Front Oncol. 2024; 14:1474267.

PMID: 39558949 PMC: 11570407. DOI: 10.3389/fonc.2024.1474267.


The Application of microRNAs in Papillary Thyroid Cancer: A Bibliometric and Visualized Analysis.

Zhang T, Yuan B, Yu S Int J Gen Med. 2024; 17:4681-4699.

PMID: 39429957 PMC: 11490214. DOI: 10.2147/IJGM.S487239.


MicroRNA Profiling in Papillary Thyroid Cancer.

Armos R, Bojtor B, Papp M, Illyes I, Lengyel B, Szili B Int J Mol Sci. 2024; 25(17).

PMID: 39273308 PMC: 11395536. DOI: 10.3390/ijms25179362.


References
1.
Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A . Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2016; 35(39):5214. DOI: 10.1038/onc.2016.139. View

2.
Lee Y, Lim Y, Lee J, Wang S, Park H, Kim S . Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer. Oral Oncol. 2014; 51(1):77-83. DOI: 10.1016/j.oraloncology.2014.10.006. View

3.
Hammond S . An overview of microRNAs. Adv Drug Deliv Rev. 2015; 87:3-14. PMC: 4504744. DOI: 10.1016/j.addr.2015.05.001. View

4.
Agretti P, Ferrarini E, Rago T, Candelieri A, De Marco G, Dimida A . MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. Eur J Endocrinol. 2012; 167(3):393-400. DOI: 10.1530/EJE-12-0400. View

5.
Acibucu F, Dokmetas H, Tutar Y, Elagoz S, Kilicli F . Correlations between the expression levels of micro-RNA146b, 221, 222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers. Exp Clin Endocrinol Diabetes. 2014; 122(3):137-43. DOI: 10.1055/s-0034-1367025. View